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BB-Cl-Amidine as a novel therapeutic for
canine and feline mammary cancer via
activation of the endoplasmic reticulum
stress pathway
Melissa M. Ledet1, Robyn Anderson1, Rebecca Harman1, Aaron Muth2, Paul R. Thompson2, Scott A. Coonrod1
and Gerlinde R. Van de Walle1*
Abstract
Background: Mammary cancer is highly prevalent in dogs and cats and results in a poor prognosis due to critically
lacking viable treatment options. Recent human and mouse studies have suggested that inhibiting peptidyl arginine
deiminase enzymes (PAD) may be a novel breast cancer therapy. Based on the similarities between human breast
cancer and mammary cancer in dogs and cats, we hypothesized that PAD inhibitors would also be an effective
treatment for mammary cancer in these animals.
Methods: Canine and feline mammary cancer cell lines were treated with BB-Cl-Amidine (BB-CLA) and evaluated for
viability and tumorigenicity. Endoplasmic reticulum stress was tested by western blot, immunofluorescence, and
quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Canine and feline mammary cancer xenograft
models were created using NOD scid gamma (NSG) mice, and were treated with BB-CLA for two weeks.
Results: We found that BB-CLA reduced viability and tumorigenicity of canine and feline mammary cancer cell lines in
vitro. Additionally, we demonstrated that BB-CLA activates the endoplasmic reticulum stress pathway in these cells by
downregulating 78 kDa Glucose-regulated Protein (GRP78), a potential target in breast cancer for molecular therapy,
and upregulating the downstream target gene DNA Damage Inducible Transcript 3 (DDIT3). Finally, we established a
mouse xenograft model of both canine and feline mammary cancer in which we preliminarily tested the effects of BB-
CLA in vivo.
Conclusion: We propose that our established mouse xenograft models will be useful for the study of mammary
cancer in dogs and cats, and furthermore, that BB-CLA has potential as a novel therapeutic for mammary cancer in
these species.
Keywords: Peptidyl arginine deiminase, Endoplasmic reticulum stress, Mammary cancer, BB-cl-Amidine
Background
Mammary cancer is highly prevalent in dogs and cats,
representing the most common cancer in intact bitches
and the third most common neoplasm in queens [1, 2].
There are five basic classes of mammary cancer treat-
ments in dogs and cats: surgery, radiation therapy,
chemotherapy, hormone therapy and immunotherapy.
Because the effectiveness of the latter four therapies is
uncertain, surgery remains the treatment of choice [3].
Unfortunately, tumor recurrence after surgery is common
in both species and adjuvant treatment with chemothera-
peutics often fails [4–6]. Therefore, there is an urgent
need to develop more effective treatments for feline and
canine mammary cancer.
Recent human and mouse studies have suggested that
peptidyl arginine deiminase enzymes (PAD) could repre-
sent a novel target for epigenetic cancer therapy. The
PAD family is made up of 5 (PAD1–4 and PAD6)
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calcium-dependent enzymes that convert positively
charged arginine residues to neutrally charged citrulline
target proteins, such as histones, in a process called
citrullination [7]. PAD are involved in cell differentiation,
apoptosis, embryonic development and gene regulation,
and each PAD isozyme has a unique tissue distribution
pattern and substrate preference, which most likely con-
fers biological specificity [7]. PAD2 represents the ances-
tral PAD family member and is abundantly represented
in female reproductive tissues, including the mammary
gland [8]. PAD2 activity was found to be significantly in-
creased during human breast cancer progression and to
be predictive of human breast cancer recurrence [9, 10].
Interestingly, PAD2 was recently identified in feline and
canine carcinomas, suggesting that this oncogene may
also play an important role in mammary cancer of small
companion animals [11]. PAD4 was initially identified in
hematopoietic cells, and elevated expression of PAD4
has been observed in various malignant tumors [12, 13].
More recently, PAD4 was also found to be highly
expressed in tumorigenic human breast cancer cell lines
that are resistant to conventional therapeutics [14].
However, the expression of PAD4 in feline or canine
mammary cells has not been previously studied. A broad
PAD inhibitor, Cl-Amidine, has been shown to have re-
markable effects on human breast cancer in vitro and in
vivo in a mouse xenograft model [10]. A more recent
study by Wang et al. showed that the PAD4 inhibitor,
YW3–56, triggers breast cancer cell death by inducing
the endoplasmic reticulum (ER) stress response [15, 16].
Cancer cells are frequently exposed to exogenous and
endogenous insults that induce ER stress. ER stress nor-
mally activates an intricate pathway with the goal of re-
storing homeostasis; however, if this stress is too
prolonged or severe, cell death will occur [17–19].
Mammary cancer in dogs and cats is similar to human
breast cancer in histology, gene expression, and meta-
static pattern. Given these similarities, PAD inhibitors
could potentially serve as novel therapeutics for mam-
mary cancer in these species as well [20]. To begin
exploring this possibility, we evaluated the effects of BB-
Cl-Amidine (BB-CLA), a more potent derivative of Cl-
Amidine [21], on normal and tumoral canine and feline
mammary cells in vitro and in vivo, and studied the
potential mechanisms underlying these effects.
Methods
Cell lines
The immortalized, non-malignant canine mammary epi-
thelial cell line (CMEC), established in-house as previ-
ously described [20], the canine mammary carcinoma
cell line REM134 [22], the immortalized, non-malignant
feline mammary epithelial cell line (FMEC), a kind gift
from Dr. John Parker (Baker Institute for Animal Health,
Cornell University, Ithaca, NY) [23], and the feline
mammary adenocarcinoma cell line K12–72.1, a kind
gift from William Hardey Jr. (School of Veterinary Medi-
cine, Cornell University, Ithaca, NY) [24], were cultured
in DMEM supplemented with 10% fetal bovine serum
(Atlanta Biologicals, Lawrenceville, GA) and 1% penicil-
lin/streptomycin. All cell lines were maintained at 37 °C
in a humidified environment with 5% CO2.
Antibodies and chemicals
The rabbit anti-human PAD2 and PAD4 antibodies were
obtained from Proteintech (12110–1-AP; Rosemont, IL)
and Sigma-Aldrich (P4749; St. Louis, MO), respectively.
The rabbit anti-human caspase-3, activating transcrip-
tion factor 4 (ATF4), 78 kDa Glucose-regulated Protein
(GRP78) and beta actin antibodies were obtained from
Abcam (ab4051; Cambridge, UK), Santa Cruz Biotech-
nology (sc-200; Dallas, TX), LS Bio (LS-C312961; Seattle,
WA), and Abcam (ab8227), respectively. The mouse
anti-dog/cat estrogen receptor alpha (ERα) antibody was
obtained from Thermo Fisher Scientific (MA5–13065;
Waltham, MA). The human anti-modified citrulline
antibody was obtained from Millipore (MABS487;
Darmstadt, Germany). Alexa 488-conjugated goat anti-
rabbit antibodies, HRP-conjugated goat anti-mouse anti-
bodies, HRP-conjugated goat anti-rabbit and HRP-
conjugated goat anti-human antibodies were all obtained
from Jackson ImmunoResearch Labs (West Grove, PA).
The PAD inhibitor, BB-CLA, was synthesized as previ-
ously described and diluted in dimethyl sulfoxide
(DMSO) [25].
Cell viability assays
After 48 h of treatment with either BB-CLA (0 to
20 μM) or DMSO (control), a 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) in vitro
toxicology assay (Sigma-Aldrich) was carried out per
manufacturer’s instructions and absorbance was mea-
sured at 570 nm on a Multiskan EX plate reader
(Thermo Fisher Scientific). Optical densities of wells
treated with BB-CLA were compared with those treated
with equivalent amounts of DMSO to determine cell via-
bility. Values were expressed relative to DMSO treated
wells.
Soft agar assays
Cells were detached using (0.25%) Trypsin-EDTA (Corn-
ing Life Sciences, Manassas, VA) and counted. Soft agar
assays were performed as previously described [26]. To
this end, 2 mL of 0.6% 2-hydroxyethylagarose melted in
appropriate culture medium were pipetted into wells of
6-well culture plates and plates were held at 4 °C for
15 min until the agarose solidified. Ten thousand cells
per well were gently resuspended in 1.5 mL 0.3% 2-
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hydroxyethylagarose melted in appropriate culture
medium with either DMSO or 10 μM BB-CLA, and lay-
ered over the base agarose. Cells were cultured in soft
agar for 14 days at 37 °C with 5% CO2. Every 3 days, cul-
tures were fed with 1 mL 0.3% 2-hydroxyethylagarose
melted in appropriate culture medium with either
DMSO or BB-CLA. Cultures were photographed at 10×
using a Nikon Diaphot-TMD inverted light microscope
with an attached Cohu CCD camera (Nikon, Melville,
NY). The number of spheres, defined as clusters of cells
increasing in size due to cell division [20], in 30 fields
were counted.
Gene expression analyses
Cells were seeded at a density of 2 × 105 in T25 tissue
culture flasks. After 24 h, culture medium was removed,
cell monolayers were rinsed with PBS, and cells were
incubated in either 10 μM BB-CLA or DMSO for 3 or
6 h. Subsequently, mRNA was extracted from the cells
using an RNeasy Plus Kit (QIAGEN, Valencia CA) and
cDNA was synthesized using M-MLV Reverse Tran-
scriptase (USB, Cleveland, OH), both according to man-
ufacturer’s protocols. The amplification reactions were
performed using Invitrogen reagents (Life Technologies)
and an Eppendorf Mastercycler. Following standard gel
electrophoresis, products were visualized using a Chemi-
Doc MP Imaging System (Bio-Rad). SYBER green-based
quantitative reverse transcriptase polymerase chain reac-
tion (qRT-PCR) assays were carried out on an Applied
Biosytems 7500 Fast Real Time PCR instrument (Ap-
plied Biosystems, Carlsbad, CA) to determine fold
changes in gene expression. The comparative Ct method
was used to quantify gene expression levels where ΔΔCt
=ΔCt (sample) – ΔCt (reference). The reference genes
Ribosomal Protein L 32 (RPL32) and Ribosomal Protein
L 17 (RPL17) were used to normalize canine and feline
samples, respectively. Primers to amplify RPL32, RPL17,
PAD2, PAD4, ERα, DNA Damage Inducible Transcript 3
(DDIT3), and DNA Damage Inducible Transcript 4
(DDIT4) were designed using Primer3 software, based
on canine and feline sequences found in the National
Center of Biotechnology Information (NCBI) GenBank.
Primer sequences are listed in Table 1. All samples were
run in triplicate.
Flow cytometry analyses
Cells were collected using accutase (Innovative Cell
Technologies, San Diego, CA), fixed for 15 min in 4%
paraformaldehyde (PFA), permeabilized and blocked in
0.1% Triton-X with 1% normal goat serum in PBS with
1% bovine serum albumin BSA for 1 h, and stained with
PAD2 or PAD4 antibodies, diluted 1:50 in PBS with 1%
BSA, for 1 h. Staining with an isotype control antibody
(Abcam), diluted 1:50 in PBS with 1% BSA, or no anti-
body stain were included as controls. Cells were washed
three times in PBS and incubated with Alexa 488-
conjugated secondary goat anti-rabbit antibodies diluted
1:500 in PBS with 1% BSA, for 30 min. After washing,
10,000 cells were analyzed on a Gallios flow cytometer
controlled by Kaluza for Gallios software (Beckman
Coulter, Indianapolis, IN). Data analysis was conducted
using Kaluza Analysis software (Beckman Coulter, In-
dianapolis, IN).
Western blot (WB) analyses
Cells were lysed in RIPA buffer containing a 1X general
protease inhibitor. Protein concentration was deter-
mined with a BCA protein assay (Thermo Fisher Scien-
tific) prior to gel loading to ensure loading of an equal
amount of protein (40 μg). 6X reducing sample buffer
was added to yield a final concentration of 1X and ly-
sates were boiled for 10 min at 95 °C. Samples were sub-
jected to SDS polyacrylamide gel electrophoresis on a
10% gel and transferred to Immobilin PVDF membranes
Table 1 Primers used in the study
Species Gene Forward Primer (5′→ 3′) Reverse Primer (5′→ 3′)
Canine RPL32 TTGAAGTGCTGCTGATGTGC GGGATTGGTGACTCTGATGG
Feline RPL17 AAGAACACACGGGAAACTGC CTGGGCACACCTACCAACTC
Canine PAD2 AGCAAGCGGATCACCATC ATGTCACGGTTCCAGTCCAG
Feline PAD2 CAGCAAGCGAATCACCATC AGGATGTCACGGTTCCAGTC
Canine PAD4 GTCGGGAGGAAGAAGTACCC CATCTCCTGGCTCTCCTTG
Feline PAD4 AGGACGTTCTGTCCAACGAG GCTTTAACACCTCCCGGTTC
Canine ERα AGGAAGAATGTTGAAACACAAAC AGCAAGTTAGGAGCAAAGAAGAG
Feline ERα ATGTTGCTGGCTACGTCATCTC GGTCCTTCTCTTCCAGAGACTTC
Canine DDIT3 AGCTGGAAGCCTGGTATGAG CAGTCAGCCAAGCCAGAGAG
Feline DDIT3 AGCTGGAAGCCTGGTATGAG CAGAGAGGCAGGGTCAAGAG
Canine DDIT4 CTGGACAGCAGCAACAGTG CATCAGGTTGGCACACAAG
Feline DDIT4 CTGGACAGCAGCAACAGTG GCACACAAGTGCTCATCCTC
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(Millipore, Billerica, MA) using a transblot turbo system
(Biorad, Hercules, CA). Membranes were blocked in 5%
BSA diluted in Tris buffered saline (TBS) and incubated
with PAD2 or PAD4 antibodies diluted 1:1000, GRP78
antibodies diluted 1:500, ERα antibodies diluted 1:200,
or modified-citrulline antibodies diluted 1:1000 in TBS
for 1 h room temperature (RT) on a rotating platform.
Blots were washed for 50 min (10 × 5 min) with TBS-
Tween, then incubated with HRP conjugated secondary
antibodies for 1 h at RT. All blots were washed for
50 min (10 × 5 min) with TBS-Tween and then visual-
ized by chemiluminescence using Clarity Western ECL
(BioRad, Hercules, CA). Membranes were stripped and
probed with beta actin antibodies, diluted 1:5000, as a
loading control. Gels were imaged on a BioRad Chemi-
Doc MP system (BioRad) and band intensities were de-
termined using Image Lab software. Intensities of the
bands of interest were divided by the intensities of load-
ing control bands to calculate relative band intensity.
Immunofluorescence (IF)
Cells for IF were grown in 24 well culture dishes fitted
with 35 mm coverslips, rinsed with PBS and fixed in 4%
PFA for 10 min. Following 3 rinses with PBS, cells were
permeabilized using PBS + 1% Triton-X 100 + 1% BSA
for 30 min at RT. Primary antibodies against PAD2,
PAD4, ATF4, all at 1:50 dilution in PBS, or Caspase-3 at
1:100 dilution, were added to the wells for 1 h at 37 °C.
Wells were rinsed 3 times with PBS and Alexa 488-
conjugated secondary antibodies were added to appro-
priate wells. After 30 min at RT, cells were washed 3
times with PBS and DAPI was added for 5 min. After a
PBS wash, coverslips were removed from wells and
mounted on slides using mounting medium (Dako, Car-
penteria, CA). Cells were examined with a Zeiss LSM
confocal microscope (Oberkochen, Germany) and im-
ages were captured with a camera controlled by ZEN
imaging software. Nine images per sample, approxi-
mately 250 cells, were analyzed and DAPI-PAD co-
localization was quantified using Image J Software.
Generation of REM134 and K12.72.1 xenografts
Both REM134 and K12.72.1 xenograft tumors were gen-
erated by injecting 1 × 106 cells in 0.1 mL Matrigel (1:1)
(BD Biosciences, San Jose, CA, USA) subcutaneously
near the nipple of gland #4 in 6-week old female NOD
scid gamma (NSG) mice (Taconic, Germantown, NY,
USA), as previously reported for mammary xenograft
models [10]. After two weeks, intraperitoneal injections
of BB-CLA (1 mg/kg/day) or vehicle control (PBS) were
initiated and carried out for 14 days. Tumor diameter
was measured daily by digital caliper and the volume
(mm3) was calculated using the formula: a2 x b/2, where
“a” is the shortest diameter and “b” is the longest
diameter of the tumor. Results are reported as mean ±
SD. After 14 days, tumors were removed and added to
10% buffered formalin. Parrafin sections were stained
with hematoxylin and eosin to determine for mitotic
rate and necrosis. A rodent pathologist estimated the
percent of necrosis by looking at the entire tumor at low
power. For mitotic rate, the number of mitotic figures
were counted in the area with the highest mitotic rate in
a 400× field. To measure apoptosis, a Terminal
deoxynucleotidyl transferase (TdT) dUTP Nick-End La-
beling (TUNEL) assay (Sigma-Aldrich) was used accord-
ing to manufacturer’s instructions and images were
quantified using Image J Software. Three mice per group
were used for each treatment. All mouse experiments
were reviewed and approved by the Institutional Animal
Care and Use Committees (IACUC) at Cornell Univer-
sity (#2013–0022).
Statistical analyses
All experiments were repeated at least three times and
results were expressed as the mean ± STDEV from three
independent experiments. Data were analyzed by the
Student’s T-test and MTT assays were analyzed by one-
way ANOVA and p values < 0.05 were considered statis-
tically significant. * indicates P < .05, ** P < .01, *** P
< .001, and **** P < .0001.
Results
BB-CLA selectively inhibits growth of canine and feline
mammary tumor cells compared to normal mammary
epithelial cells
To start exploring the potential of peptidyl arginine dei-
minase enzyme (PAD) inhibitors as anti-cancer drugs to
treat canine and feline mammary cancer, the tumoral
cell lines REM134 (canine) and K12–72.1 (feline) were
incubated with increasing doses of BB-Cl-Amidine (BB-
CLA) for 48 h and evaluated for viability using MTT as-
says. A dose-dependent decrease in cell viability was ob-
served in both tumoral cell lines and reached
significance starting at 1 μM for both REM134 and
K12–72.1 (Fig. 1a). Importantly, this effect on cell viabil-
ity was lower in non-malignant canine (CMEC) and
feline (FMEC) mammary cells, and for FMEC, only be-
came statistically different at the higher doses of BB-
CLA, indicating that this drug preferentially affects
tumoral cells (Fig. 1a). A significant difference in effect
between non-malignant and tumoral cells was observed
beginning at 1 μM for feline cells and 5 μM for canine
cells (Fig. 1a). We used 10 μM BB-CLA for all future
experiments, based on the significant effect on viability
of the tumoral cells from both species. To follow up on
the underlying mechanism for the reduced viability after
BB-CLA treatment, cells were stained for caspase-3 at
6 h post BB-CLA treatment. In contrast to non-treated
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REM134 and K12–72.1, BB-CLA-treated cells stained
positive for caspase-3, indicating that the cells under-
went apoptosis in response to BB-CLA (Fig. 1b). We
then evaluated the effect of BB-CLA on tumorigenicity
by using soft agar assays, which are established to be
good predictors of in vivo tumorigenicity [10]. An
equivalent amount of DMSO was added to a separate
set of wells as a control. Compared to the control cells,
REM134 and K12–72.1 treated with BB-CLA formed
significantly fewer spheres and these spheres were
significantly smaller (Fig. 1c).
Normal and tumoral feline and canine mammary cells
express similar levels of PAD2 and PAD4
To date, no data are available on the expression of PAD
enzymes in canine or feline mammary cell lines. There-
fore, we decided to evaluate PAD expression in both
normal and tumoral canine and feline cell lines, to see
Fig. 1 Effect of BB-CLA on viability and tumorigenicity of canine and feline mammary cancer cell lines. a Cells were treated for 48 h with different
concentrations of BB-CLA and viability was evaluated using MTT assays. Values are expressed relative to cells treated with DMSO (control). Letters
indicate significant differences between doses for each cell line (one-way ANOVA) and asterisks indicate significant differences between cell lines
(T-test). b Cells were treated for 6 h with 10 μM BB-CLA and probed with antibodies to Caspase-3. Representative images are shown. c Soft agar
assays were established in which cells were treated with 10 μM BB-CLA or DMSO (control). Representative images after two weeks of treatment
(i) and quantification of spheres (ii) are shown. Scale bar: 10 μm. *P < 0.05, ***P < 0.001, ****P < 0.0001, n = 3. Data are presented as
mean ± standard deviation
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whether a differential expression could be observed
similar to what has been described for the human
MCF10AT mammary cell line series, where PAD2 was
more abundantly expressed in the tumoral cell lines
compared to the normal MCF10a cell line [9, 11]. We
looked at PAD2 and PAD4 specifically, since these
enzymes have been described to be expressed in the
mammary gland [11]. First, we used quantitative (q) RT-
PCR to compare mRNA expression levels of these two
PAD enzymes in the different cell lines, and in contrast
to the human results, PAD2 mRNA expression levels
were virtually indistinguishable between normal and
tumoral cells of both canine and feline origin (Fig. 2a).
PAD4 mRNA levels were also similar between normal
and tumoral canine mammary cells and a slight, but
significant, increased expression was observed in the
feline tumoral cell line K12–72.1 compared to normal
FMEC, as indicated by the lower ΔCT values (Fig. 2a).
Next, we evaluated PAD2 and PAD4 expression on a
protein level, since the level of translation of PAD2 and
PAD4 could be different between normal and tumoral
cells. Western Blot (WB) analyses showed that PAD2
and PAD4 proteins were expressed similarly in normal
and tumoral cells of both species (Fig. 2b). Flow cytome-
try analyses corroborated these findings (Fig. 2c), and
combined with the qRT-PCR results, led us to conclude
that PAD2 and PAD4 are expressed at similar levels in
normal and tumoral canine and feline mammary cell
lines. Finally, we determined the relative amount of
citrulline in the cells as a measure of PAD activity using
Fig. 2 Expression of PAD2 and PAD4 in non-malignant and tumoral canine and feline mammary cell lines. a Expression levels of the genes PAD2
and PAD4 in canine and feline normal and tumoral mammary cell lines as determined by qRT-PCR. b Protein expression in whole cell lysates
subjected to SDS-PAGE and immunoblot analyses probed with PAD2 or PAD4 antibodies. β-actin was included as a loading control. Representa-
tive Western blots and quantifications are shown. Quantification is represented as the fold change of PAD2/4 band density over β-actin band
density. c Protein expression in cells probed with either PAD2 or PAD4 antibodies and subjected to flow cytometry analyses. d Protein expression
in whole cell lysates subjected to SDS-PAGE and immunoblot analyses probed with anti-modified citrulline antibodies. β-actin was included as a
loading control. Representative Western blots and quantifications are shown. Quantification is represented as the fold change of modified-
citrulline band density over β-actin band density. *P < 0.05, n = 3. Data are presented as mean ± standard deviation
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a modified anti-citrulline antibody, as previously
described [27, 28]. No difference was detected by west-
ern blot (Fig. 2d), further supporting that the levels of
PAD enzymes are similar in these canine and feline non-
malignant and tumoral cell lines. Since immunohisto-
chemistry studies previously showed a decrease in PAD2
nuclear staining in canine and feline mammary carcin-
oma tissues compared to normal mammary epithelial
tissues [26, 29], we decided to evaluate the cellular
localization of PAD2 and PAD4 in our cell lines using
immunofluorescence (IF). We found that PAD2 was
primarily located in the nuclei of the cells, irrespect-
ive of species or disease status (normal versus tu-
moral) (Fig. 3a & b). PAD4 was expressed in both
nuclei and cytoplasm, but PAD4 nuclear expression
was lower in tumoral cells compared to normal mam-
mary cells in both species, which reached significance
in canine, but not feline cells (Fig. 3a & b).
BB-CLA activates the endoplasmatic reticulum (ER) stress
pathway in canine and feline tumoral mammary cells
Our data showing no differential expression of both
PAD2 and PAD4 between normal and tumoral mam-
mary epithelial cells seems to indicate that PAD inhib-
ition is not the primary mechanism for the observed BB-
CLA-induced cell death and reduced tumorigenicity of
the tumoral cells, as previously reported [16]. Indeed, no
changes in citrullination were observed 6 h post treatment
(Additional file 1: Figure S1), although upstream inhibition
of PAD activity cannot be ruled out completely. So we
Fig. 3 Cellular localization of PAD2 and PAD4 in non-malignant and tumoral canine and feline mammary cell lines. Protein localization in cells
probed with PAD2 or PAD4 antibodies and subjected to immunofluorescence. Representative fluorescence pictures (a) and quantifications, using
Image J Software, (b) are shown. **P < 0.01, n = 3. Data are presented as mean ± standard deviation
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decided to explore whether endoplasmic reticulum (ER)
stress activation could be the mode of action of BB-CLA
in our canine and feline tumoral cells, based on a recent
study where the activation of this pathway was demon-
strated in estrogen receptor (ERα)-negative breast cancer
cells using another PAD inhibitor [19, 30]. Before evaluat-
ing the ER stress activation pathway, we first confirmed
the ERα negative status of our different cell lines, both at
the mRNA and protein level (Additional file 2: Figure S2A
& B). To study the ER stress pathway in more detail, three
important checkpoints in this pathway were evaluated: (i)
expression of 78 kDa Glucose-regulated Protein (GRP78),
a chaperone protein in the unfolded protein response
pathway [16], (ii) localization of Activating Transcription
Factor 4 (ATF4), a transcriptional activator that regulates
induction of proteins in response to ER stress [31], and
(iii) expression of the DNA Damage Inducible Tran-
script 3/4 (DDIT3/4) genes, which are multifunctional
transcriptions factors induced by ATF4 [32, 33]. GRP78 is
upregulated in a variety of cancer cell lines and is elevated
in primary breast tumors compared with benign mam-
mary tissue [19, 30]. After ER stress, GRP78 is titrated
away which releases its hold on the ER-transmembrane
signaling molecules and activates the unfolded protein re-
sponse pathway [16]. Using WB analyses, we could detect
a significant decrease in GRP78 expression in both canine
and feline tumoral cells in the presence of BB-CLA at 3 h
post treatment, indicating that BB-CLA activates the early
steps in the ER stress pathway and may represent a novel
therapeutic for targeting GRP78 (Fig. 4a). Concurrently, IF
staining for ATF4 showed a significant increase in nuclear
localization of ATF4 in canine tumoral cells at 3 h and 6 h
post BB-CLA treatment (Fig. 4b(i) & (ii), respectively). In
contrast, nuclear ATF4 expression was already present in
feline tumoral cells, even before BB-CLA treatment, and
did not significantly increase at 3 h or 6 h post BB-CLA
treatment (Fig. 4b(i) & (ii), respectively). Since translocali-
zation of ATF4 into the nucleus results in transcription of
several downstream genes such as DDIT3 and DDIT4
[34–36], we decided to determine the expression of these
genes after BB-CLA treatment using qRT-PCR. We found
a significantly increased expression of DDIT3, but not
DDIT4, in both canine and feline tumoral cells at 6 h post
BB-CLA when compared to DMSO-treated, control
tumoral cells (Fig. 5a). This increase in DDIT expression
was not seen in the non-malignant mammary cells of both
species, i.e. FMEC or CMEC, treated with BB-CLA, indi-
cating that this was a tumor cell-specific response (data
not shown). Collectively, these data indicate that BB-CLA-
induced cell death in the canine and feline mammary can-
cer cell lines REM134 and K12.72.1, respectively, occurs
in part via the activation of the ER stress pathway and
could explain the difference in susceptibility to BB-CLA
between normal and tumoral cells (Fig. 5b).
Generation of canine and feline mammary cancer
xenograft mice
To test the efficacy of BB-CLA in vivo on tumors
derived from the same cell lines used in our in vitro
experiments, we created a mammary cancer xenograft
model of each species using the REM134 (canine) and
K12.72.1 (feline) cell lines. Although several canine, and
one recent feline, mammary tumor xenograft models
have been developed previously [37], these cell lines
have not been used in an orthotopic xenograft, so we
needed to validate the model with our cell lines first. To
this end, mice were injected with cells in a 1:1 ratio with
Matrigel in the 4th mammary gland and reproducibly
developed a prominent mammary tumor within two and
four weeks for REM134 and K12.72.1, respectively.
These were all squamous cell carcinomas that appeared
to be derived from mammary duct epithelium, and in
some tumors, remnant ducts surrounded by myoepithe-
lial cells and lined by neoplastic cells, were evident. The
average tumor volume ranged around 353.45 ± 106.
96 mm3 and 204.02 ± 60.13 mm3 for REM134 and K12.
72.1, respectively. To preliminary evaluate the efficacy of
BB-CLA in these xenograft models, the drug was
injected intraperitoneally for two weeks at 1 μg/ml, as
this dose was previously described to be nontoxic in
mice [10]. During the treatment period, BB-CLA-treated
mice were observed for changes in tumor appearance
compared to the control mice in both xenograft models,
and it was found that BB-CLA-treated tumors became
crusty and the surrounding skin showed hair loss (Fig. 6a).
Despite these striking visible changes, no difference in vol-
ume was observed during the two-week injection period
(Fig. 6b). Histological examination yielded no difference in
necrosis between control and treated tumors (Fig. 6c) and
a slight difference in mitotic rate in the feline xenograft
tumors (Fig. 6d). There was an increase in the percentage
of apoptotic cells in the BB-CLA-treated canine xenograft
tumors compared to the controls (Fig. 6e), similar to our
in vitro data where apoptotic cells were observed in the
BB-CLA-treated, but not untreated, cells (Fig. 1b). There
was a slight increase in apoptotic cells in the BB-CLA-
treated feline xenograft tumors also, however, this did not
reach significance (Fig. 6e).
Discussion
This study was initiated to evaluate the efficacy of the
peptidyl arginine deiminase (PAD) inhibitor BB-Cl-
Amidine (BB-CLA) on canine and feline mammary can-
cer cell lines in vitro and in vivo. Our salient findings
were that BB-CLA reduces the viability and tumorigen-
icity of canine and feline mammary cancer cell lines at
low concentrations, via the activation of the endoplasmic
reticulum (ER) stress pathway, with no to minimal ef-
fects on the viability of normal mammary cells. This
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Fig. 4 Endoplasmic reticulum (ER) stress activation in canine and feline tumoral mammary cell lines after treatment with BB-CLA. a Whole cell
lysates treated for 3 h with DMEM (untreated), DMSO (control), or 10 μM BB-CLA were subjected to SDS-PAGE and immunoblot analyses probed
with 78 kDa glucose-regulated protein (GRP78). β-actin was included as a loading control. Representative Western blots and quantifications are
shown. Quantification is represented as the fold change of GRP78 band density over β-actin band density. b Cells were treated with BB-CLA for
3 h (i) and 6 h (ii), probed with ATF4 antibodies and subjected to immunofluorescence. Representative fluorescence pictures and quantifications,
using Image J Software, are shown. *P < 0.05, n = 3. Data are presented as mean ± standard deviation
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study also provided the first description of PAD4, and a
more in-depth description of PAD2, expression in normal
and tumoral mammary cells from canine and feline origin.
In addition, we report on the generation of xenograft
models using the cell lines REM134 and K12.72.1, and the
preliminary evaluation of BB-CLA efficacy in these models.
In contrast to what has been described previously for
human breast cell lines, we found a similar PAD2 and
PAD4 expression between normal and tumoral mam-
mary canine and feline cell lines. One explanation for
this discrepancy between species is based on the source
of the cells that were used. McElwee et al. found higher
PAD2 expression in human breast cancer cells compared
to normal mammary epithelial cells using the MCF10AT
mammary cell line series in which the tumor cells were
developed from the transformed normal mammary
MCF10a cell line, and thus all cells have the same cell of
origin [10, 38, 39]. In our study, the normal and tumoral
feline and canine cell lines being compared were devel-
oped from different individuals for both species. There-
fore, inter-animal variations in PAD2 and PAD4 levels
could explain why no differences were detected between
normal and tumoral cells in the present study. It would
be interesting in future work to look at PAD2 and PAD4
expression in primary tumor and healthy tissue samples
instead of cell lines and/or to use cell line series originat-
ing from the same animal, similar to the MCF10AT cell
lines series, to determine if there are indeed inter-animal
variations. Another explanation for the observed
discrepancy could be the receptor status of the cell lines
used. Previous data on PAD2 and PAD4 expression in
human breast cells were primarily generated using estro-
gen receptor alpha (ERα)-positive breast cancer cells
[10], whereas the canine and feline cell lines used in this
study were ERα negative. This explanation is further
supported by previous studies showing that PAD2 is
more abundantly expressed in the luminal breast cancer
subtype, which is ERα positive [16]. Additional studies
should evaluate PAD expression in ERα-positive feline
and canine mammary cancer cells to determine if ERα
expression is indeed correlated with PAD expression.
Our results showed that treatment with the PAD
inhibitor BB-CLA in canine and feline mammary cancer
cells resulted in an activation of the ER stress pathway.
This is in line with a recent study from Wang et al.,
showing that YW3–56, another PAD inhibitor, initiated
the ER stress pathway through activation of ATF4 in
human breast cancer cells, leading to autophagy in these
cells [1, 2]. When evaluating the different genes and pro-
teins involved in the ER stress pathway in our canine
and feline cell lines, some interesting observations were
made. First, we observed a difference in ATF4
localization between feline and canine mammary cancer
cells, irrespective of BB-CLA treatment, and so we like
to postulate that these inherent differences may be re-
flective of the tumoral malignancy in vivo. It is known
Fig. 5 DDIT3 gene expression indicates endoplasmic reticulum (ER) stress activation after treatment with BB-CLA. a Expression levels of DDIT3 and
DDIT4 mRNA in canine and feline and tumoral mammary cell lines after 6 h of BB-CLA or DMSO (control) treatment as determined by qRT-PCR.
**P < 0.01, ***P < 0.001. b Schematic representation of the findings presented in this study. In normal cells, baseline ER stress is low, thus any stress
as a result of BB-CLA treatment is managed by the pathway at low concentrations. In tumor cells, where baseline ER stress is already high, any
additional stress from BB-CLA treatment overloads the pathway leading to the initiation of cell death pathways. n = 3. Data are presented as
mean ± standard deviation
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that feline mammary cancer is on average more aggressive
than canine mammary cancer, with 80% of mammary tu-
mors being malignant in cats versus 50% being malignant
in dogs, and consequently, that mammary cancer in cats
has a worse prognosis [40, 41]. Also, we observed that the
feline tumoral cells were more responsive to BB-CLA
compared to canine tumoral cells and in parallel, we
found that untreated feline cells have inherently more nu-
clear ATF4 and thus are at a higher baseline ER stress
level. Since BB-CLA stimulates the ER stress pathway, this
could explain why a greater effect was seen with this drug
in the feline cells. Second, we observed a significant up-
regulation of the gene DDIT3, but not DDIT4, after BB-
CLA treatment in both feline and canine mammary can-
cer cell lines, which could indicate that BB-CLA is pro-
moting activation of the apoptosis pathway rather than
the autophagy pathway in response to ER stress [18, 42–
44]. Indeed, cells were positive for Caspase-3, a marker of
apoptosis, after treatment with BB-CLA, indicating this is
likely the predominant method for cell death after ER
stress in these cells.
Despite the use of REM134 and K12.72.1 cell lines in
canine and feline mammary cancer research, there were
no reports of mouse orthotopic xenografts utilizing
these cell lines prior to this study. REM134 has previ-
ously been used in xenografts after subcutaneous inocu-
lation [22, 45], however orthotopic xenografts offer the
advantage of a tumor microenvironment that leads to
the development of tumor cells more biologically similar
to clinical cases and with metastatic potential [46–48].
We found that tumors can be induced in the mammary
gland reproducibly in NOD scid gamma (NSG) mice
using these cell lines. Unfortunately, when we prelimin-
ary analyzed the efficacy of BB-CLA in these xenograft
models, we did not find robust differences in tumor size,
necrosis or mitotic rates in treated versus untreated ani-
mals. A potential explanation could be the dosage of BB-
CLA used for treatment, which was based on a previous
Fig. 6 Treatment of REM134 and K12.72.1 murine xenografts. a Representative macroscopic pictures of tumor-bearing NGS mice at day 14 of
treatment with 1 mg/kg/day BB-CLA or DMSO (control). b Tumor size in mice treated with BB-CLA or control over the 14-day period. Histological
analyses showing necrosis percentage (c) and mitotic rates (d) at day 14 of treatment. e Detection of apoptosis in histological sections by
Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) assay, with quantification using Image J Software. *P < 0.05, n = 3.
Data are presented as mean ± standard deviation
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in vivo study where BB-CLA was used in a murine arth-
ritis model [49]. It is plausible that the dosage needed
for effective treatment of mammary cancer may be
higher than the dose needed for the treatment of arth-
ritis. Additionally, a longer dosage period or more fre-
quent doses may have increased effectiveness. Future
experiments in xenograft models of mammary cancer
are needed to define the optimal effective BB-CLA dose.
Unexpectedly, there was an increase in mitotic rate fol-
lowing treatment with BB-CLA in the K12–72.1 xeno-
graft model. This would normally be associated with a
poorer prognosis, however, the tumor volumes were
similar in both groups. BB-CLA may have had additional
effects on the tumor microenvironment that allowed for
increased aggressiveness of the tumor cells, but this is
unlikely as the mitotic rate was only increased in the
K12–72.1 tumors and not REM134 tumors. Lastly, this
finding could also be a product of low sample numbers,
which should be addressed in future studies. We did,
however, observe that the tumors in the BB-CLA-treated
mice were crusty and that the skin showed local hair
loss. A potential explanation for this observation is that
other PAD, like PAD1, PAD2, and PAD3, are expressed
in the skin of humans and rodents [8], and could have
been affected by the PAD-inhibitor BB-CLA.
Conclusions
Taken together, our in vitro study provides the first data on
the potential of BB-CLA as a novel therapeutic to treat
mammary cancer in dogs and cats. This is an exciting find-
ing given the lack of available treatments for mammary
cancer in these species. Canine and feline mammary cancer
cell lines were successfully xenografted in the mouse mam-
mary gland and will be beneficial in future research aimed
at the development of mammary cancer therapeutics.
Additional files
Additional file 1: Figure S1. BB-CLA does not affect citrullination in tu-
moral canine and feline mammary cancer cell lines. Protein expression in
whole cell lysates after 6 h of 10 μM BB-CLA treatment subjected to SDS-
PAGE and immunoblot analyses probed with anti-modified citrulline anti-
bodies. β-actin was included as a loading control. Representative Western
blots and quantifications are shown. Quantification is represented as the
fold change of modified-citrulline band density over β-actin band density.
n = 3. Data are presented as mean ± standard deviation. (TIFF 204 kb)
Additional file 2: Figure S2. Estrogen receptor expression in non-
malignant and tumoral canine and feline mammary cell lines. A. Expres-
sion of estrogen receptor alpha (ERα) mRNA in canine and feline normal
and tumoral mammary cell lines, as determined by RT-PCR. Equal cDNA
loading was determined by Ribosomal Protein L (RPL) 32 (canine) and
RPL17 (feline). Uterine tissue from each species was included as a positive
control. B. ERα protein expression in whole cell lysates subjected to SDS-
PAGE and immunoblot analyses probed with ERα antibodies. β-actin was
included as a loading control. Canine mammary tissue was used as a
positive control (+ Cont.). n = 3. Data are presented as mean ± standard
deviation. (TIFF 336 kb)
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